



HC Wainwright  
BIOCONNECT Virtual Conference  
Jan 10-13 2022

---

Dr Graham Kelly  
CEO and MD



# Disclaimer

---

This presentation has been prepared by Noxopharm Limited (NOX or the Company). It should not be considered as an offer or invitation to subscribe for, or purchase any shares in NOX, or as an inducement to purchase any shares in NOX. No agreement to subscribe for securities in NOX will be entered into on the basis of this presentation or any information, opinions or conclusions expressed in the course of this presentation.

This presentation is not a prospectus, product disclosure document, or other offering document under Australian law or under the law of any other jurisdiction. It has been prepared for information purposes only. This presentation contains general summary information and does not take into account the investment objectives, financial situation and particular needs of an individual investor. It is not a financial product advice and the Company is not licenced to, and does not provide, financial advice.

This presentation may contain forward-looking statements which are identified by words such as 'may', 'could', 'believes', 'estimates', 'targets', 'expects', or 'intends' and other similar words that involve risks and uncertainties. These statements are based on an assessment of past and present economic and operating conditions, and on a number of assumptions regarding future events and actions that, as at the date of this presentation, are expected to take place. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors many of which are beyond the control of the Company, its Directors and management.

Although the Company believes that the expectations reflected in the forward looking statements included in this presentation are reasonable, none of the Company, its Directors or officers can give, or gives, any assurance that the results, performance or achievements expressed or implied by the forward-

looking statements contained in this document will actually occur or that the assumptions on which those statements are based are exhaustive or will prove to be correct beyond the date of its making. Readers are cautioned not to place undue reliance on these forward-looking statements. Except to the extent required by law, the Company has no intention to update or revise forward-looking statements, or to publish prospective financial information in the future, regardless of whether new information, future events or any other factors affect the information contained in this presentation.

Readers should make their own independent assessment of the information and take their own independent professional advice in relation to the information and any proposed action to be taken on the basis of the information. To the maximum extent permitted by law, the Company and its professional advisors and their related bodies corporate, affiliates and each of their respective directors, officers, management, employees, advisers and agents and any other person involved in the preparation of this presentation disclaim all liability and responsibility (including without limitation and liability arising from fault or negligence) for any direct or indirect loss or damage which may arise or be suffered through use of or reliance on anything contained in, or omitted from, this presentation. Neither the Company nor its advisors have any responsibility or obligation to update this presentation or inform the reader of any matter arising or coming to their notice after the date of this presentation document which may affect any matter referred to in the presentation.

Veyonda® currently is not approved for use in Australia or any other country.

# Our fields of interest

Oncology




Acute inflammation  
- sepsis



Autoimmunity



RNA vaccine  
technology





## Our points of distinction

---

Small molecule  
drug platform

**A unique family of drugs marked by:**

- **multiple biological functions based on inhibition of protein folding (thiol-disulfide interchange) and disruption of plasma membrane function (transmembrane electron potential)**

a first-in-class means of  
addressing **multiple  
dysfunctions within the  
tumour micro-environment**

a first-in-class means of  
addressing selectively **key  
inflammatory signaling  
pathways including cGAS-  
STING and TBK1**

## Our points of distinction

Oligonucleotide  
drug platform

**A unique platform of oligonucleotides designed to minimize the unwanted triggering of inflammatory receptors**

**Oligos inhibiting cGAS-STING signaling:**

- as treatments for autoimmune diseases

**Oligos inhibiting Toll-like receptors (TLRs):**

- as treatments for TLR-driven autoimmune diseases
- to reduce inflammatory side-effects of mRNA vaccines

## Oncology programs - Veyonda<sup>®</sup>

### Suppository dosage form of idronoxil (IDX)

*(3-(4-hydroxyphenyl)-2H-chromen-7-ol)*

#### Selective inhibitor of:

- external membrane NADH oxidases
- sphingosine kinase 1
- TBK1

#### Biological functions:

- **cytostatic/cytotoxic** to most forms of cancer cells
- **inhibits DNA repair and autophagy**
- **activates CD4+ and CD8+ T-cells**
- reverses S-1-P gradient - **restores T-cell populations in tumours**



Oncology

## Oncology programs - Veyonda<sup>®</sup>

Program	Combination	Indication	Phase 1	Phase 2
DARRT	Veyonda + EBRT	Prostate, lung, breast	DARRT-1 Completed	DARRT-2 Active
IONIC	Veyonda + nivolumab	Multiple	IONIC-1 Active	
LuPIN	Veyonda + <sup>177</sup> LuPSMA-617	Prostate	LuPIN Completed	
CEP	Veyonda + chemotherapy	Soft Tissue Sarcomas	CEP-1 Completed CEP-2 in Start Up	

## DARRT-2 Trial

## Oncology programs - Veyonda®



Oncology

***Rationale: abscopal response to EBRT via autophagy inhibition + T-cell activation + tumor COLD to HOT conversion***

- Multi-national Phase 2 trial. ~100 patients
- IND received from FDA
- Active recruitment in two U.S. sites
- More sites in coming months in AUS and Europe
- Study is in 2 parts:
  - Dose escalation: 1200 mg to 2400 mg; any solid tumour
  - Dose expansion: final dose; focus on prostate cancer, breast and lung cancer





## IONIC Trial

## Oncology programs - Veyonda<sup>®</sup>

***Rationale: IDX converts tumors from COLD to HOT by reversal of intra-tumoral S-1-P gradient and activation of CD4+ and CD8+ T-cells***

- Phase 1 trial of Veyonda<sup>®</sup> + nivolumab (Opdivo<sup>®</sup>; BMS)
- Investigator initiated study; Australian only sites
- First 2 patients enrolled
- Cohort 1: Non-responding tumours to PD-1 inhibitors
- Cohort 2: PD-1 inhibitor naive tumours



Oncology



## CEP-2 Trial

## Oncology programs - Veyonda<sup>®</sup>

### ***Rationale: IDX chemo-enhancement of alkylating agents***

- Phase 1 trial of Veyonda<sup>®</sup> + doxorubicin IND from FDA received
- Soft tissue sarcomas
- Trial to be conducted in the U.S. due to strong interest
- Contract negotiations with clinical sites ongoing
- Enrolment expected shortly



Oncology

# LuPIN Trial



# Oncology programs - Veyonda®

## Rationale: IDX radio-enhancement of <sup>177</sup>Lutetium-PSMA

- Promising results have been published in peer-reviewed medical journals:
  - Any PSA reduction in 86% of patients
  - PSA fall of >50% in 61% of patients
  - Median Overall Survival of 19.7 months
- Discussions regarding potential trial in Europe currently underway



Oncology




  
NOXOPHARM

# Oncology - Pipeline



Oncology Pipeline


## A pipeline of 3 exciting new anti-cancer drugs with novel actions



# Acute Inflammation - Sepsis

Drug discovery program


Unique family of small molecule inhibitors of Tank-Binding Kinase 1 (TBK1)



Development of drugs to block the cytokine release syndrome associated with viral and bacterial infections




Acute inflammation - sepsis



# Autoimmunity

Drug discovery program

Oligonucleotides targeting **cGAS-STING**



Developing drugs for various  
chronic inflammatory/ autoimmune diseases



Autoimmunity

# RNA Vaccines


Drug discovery program

Oligonucleotides targeting Toll-like receptors (TLRs)


**Therapeutic aim = to reduce the pro-inflammatory side-effects of RNA drugs and vaccines and treat TLR-driven inflammatory diseases**

In the case of RNA vaccines, to:

- Improve their safety
- Permit higher dosages of viral antigen to be used
- Improve manufacturing efficiencies



RNA vaccine technology



# Key Metrics

(at 7 January 2022)

Market cap

**A\$124m**

Share price

**A\$0.425c**

Issued shares

**~292.2m**

Cash (at 30/9/21)

**A\$23.6 m**

**\$5.9M cash rebate rec'd Jan 2022**

## Anticipated News Flow (next 6 months)

Progress in:

- ▲ IONIC-1, DARRT-2 & CEP-2 clinical program
- ▲ Oncology drug pipeline
- ▲ Sepsis and autoimmunity disease drug discovery programs
- ▲ mRNA vaccine technology program







For further information:



[info@noxopharm.com](mailto:info@noxopharm.com)



[www.noxopharm.com](http://www.noxopharm.com)



@Noxopharm